Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

immatics Closes €34 Million Financing

Published: Tuesday, October 15, 2013
Last Updated: Tuesday, October 15, 2013
Bookmark and Share
immatics’ lead cancer vaccine IMA901 to report interim phase 3 data in 2014 and final data in 2015.

immatics biotechnologies GmbH has announced that it has closed a €34 million Series D financing round.

The funding round was supported by existing investors including dievini Hopp Biotech holding, Wellington Partners, MIG-advised funds and AT Impf GmbH. Under the terms of the fundraising, immatics will receive the first €12 million tranche of funding immediately.

The new funds will enable immatics to conclude the development of its lead vaccine IMA901, including completing all of the activities necessary to prepare for regulatory filings in the US and Europe.

IMA901 - a cancer vaccine comprising 10 different tumor-associated peptides (TUMAPs) that are found to be highly over-expressed in the majority of patients suffering from renal cell carcinoma (RCC) - is in a pivotal phase 3 trial. It has orphan drug designation in the US and Europe for the treatment of RCC in HLA-A*02 positive patients.

The phase 3 trial is designed to evaluate overall survival with IMA901 in combination with sunitinib (Sutent®, Pfizer), the current standard first-line therapy, compared with sunitinib alone in patients with metastatic and/ or locally advanced RCC.

The trial has completed inclusion of 339 patients at sites in the US and Europe. Interim overall survival results are expected in 2014, with final data in 2015.

The phase 3 trial builds on the positive phase 2 study with IMA901 in advanced RCC patients. The trial showed that patients who produced an immune response to two or more of the TUMAPs contained in IMA901 had a significantly longer survival, as published in Nature Medicine in 2012.

Paul Higham, CEO of immatics, said: “We are pleased that our existing investors have demonstrated their continued confidence in immatics and the novel cancer vaccines that we are able to generate using our unique, rational TUMAP-based approach to cancer immunotherapy. This financing will allow us to complete the full phase 3 development of IMA901 and prepare regulatory submission packages for the US and Europe. There is a clear need for novel cancer therapies that can deliver prolonged survival while maintaining a good quality of life. We remain hopeful that IMA901 will deliver a significant improvement for patients with renal cell cancer.”

Peter Chambré, Chairman of immatics’ Board, said: “The IMA901 results to date have demonstrated that immatics’ vaccines have the potential to significantly extend the life of renal cancer patients. I am delighted that our current investors have committed to backing what we believe is a very promising cancer vaccine portfolio and cancer immunotherapy approach and look forward to the IMA901 phase 3 results in the near future.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

immatics and BioNTech to Advance a Novel Class of Fully Personalized Therapeutic Cancer Vaccines
Regulatory authority approves clinical trial for Glioma Actively Personalized Vaccine Consortium (GAPVAC).
Thursday, October 16, 2014
immatics Receives €22 Million Final Tranche of Series D Fundraising
Funds will be used to complete phase 3 study with IMA901 and to invest in the expansion of immatics’ Human Immunopeptidome Program to identify the most relevant targets for cancer immunotherapies.
Thursday, July 17, 2014
Immatics to Continue Work on Vaccine (IMA950) for Glioblastoma
A new cancer vaccine (IMA950) for glioblastoma has met the two primary endpoints of safety and immunogenicity in a trial conducted by Cancer Research UK.
Thursday, April 24, 2014
Professor Dr Hans-Georg Rammensee Awarded the Bayer Hansen Family Award 2013
Prestigious Hansen Family Award recognizes Hans-Georg Rammensee’s pioneering scientific research activities.
Friday, March 08, 2013
immatics Presents Encouraging Overall Survival Data from a Phase 2 Study in CRC
T-cell responses to the IMA910 colorectal cancer vaccine peptides show a clear correlation with longer overall survival.
Monday, June 04, 2012
immatics Wins 2012 TiE50 Award
immatics chosen as a leading company in the life sciences category by the world's largest entrepreneurial network.
Friday, May 25, 2012
immatics Appoints Dr Rainer Kramer as CBO
Dr. Kramer will lead immatics’ business development unit.
Thursday, April 12, 2012
immatics Presents Positive Phase II Results with IMA910 in CRC Patients
Study shows a consistent association between immune response to IMA910 and all clinical endpoints and an excellent tolerability profile.
Wednesday, January 25, 2012
immatics Appoints Dr. Harald Stock to its Board
Dr. Stock was Chairman and Managing Director of the German DePuy Group, the orthopeadics division of Johnson & Johnson, from 2006 to the end of 2008.
Thursday, April 21, 2011
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Less May Be More in Slowing Cholera Epidemics
Mathematical model shows more cases may be prevented and more lives saved when using one dose of cholera vaccine instead of recommended two doses.
Investigating the Vape
Expert independent review concludes that e-cigarettes have potential to help smokers quit.
NIH Launches Human RSV Study
Study aims to understand infection in healthy adults to aid development of RSV medicines, vaccines.
Researchers Discover Synthesis of a New Nanomaterial
Interdisciplinary team creates biocomposite for first time using physiological conditions.
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Flu Remedies Help Combat E. coli Bacteria
Physiologists from the University of Zurich have now discovered why the intestinal bacterium Escherichia coli (E. coli) multiplies heavily and has an inflammatory effect.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!